The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according ...

The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according ...

An exhibit booth display and brochure at the American Psychiatric Association annual meeting suggested the investigational ...

With approval to treat essential thrombocytopenia, Besremi, already indicated to treat polycythemia vera, will face off ...

Cosmetic regulators from across the globe came together and agreed on general principles for minimizing barriers to trade at ...

Moderna's shift in regulatory strategy produced a massive data set to respond to vaccine safety critics, as illustrated in ...

Narver, a former assistant director in the Justice Department’s Consumer Protection Branch, became director of the Office of ...

The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and ...

Executive changes this week include Entera Bio and Rhythm Pharmaceuticals appointing new CMOs, and Longevica Therapeutics ...

Met inhibitor Orpathys and EGFR inhibitor Tagrisso combo could reshape primary treatment strategy for locally advanced or ...

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical ...

The FDA said Boston Scientific is removing its Imager II Angiographic Catheters because a manufacturing issue could cause the catheter tip to degrade and detach during use. The company has also ...